ENHANCED ANTIMETASTATIC ACTIVITY OF LYMPHOKINE-ACTIVATED KILLER CELLS PURIFIED AND EXPANDED BY THEIR ADHERENCE TO PLASTIC

Authors:
  • NVNL VUJANOVIC
    NL VUJANOVIC
  • JHJC HISERODT
    JC HISERODT

  • 15 March 1989
    • journal article
    • research article
    • Vol. 49  (6) , 1441-1446
    • PMID:2784350
Abstract
We have recently reported a simple and reproducible technique for the purification and rapid expression of homogeneous populations of large granular lymhocytes expressing a natural killer cell phenotype and high level of broad antitumor cytotoxic activity [lymphokine-activated killer (LAK) activity]. This technique exploits the observation that, in the presence of recombinant interleukin 2 (rIL-2), large granular l lymphocytes/natural killer cells become adherent to plastic surfaces, actively proliferate, and acquire high levels of LAK activity. Becauseof their proliferate, and acquire high levels of LAK activity. Becasue of their adherent properties these cells have been termedadherent LAK or A-LAK cells. The present studies investigate the antimestatic effects of A-LAK cells in a syngeneic rat model of experimental pulmonary and hepatic metastases. For pulmonary metastases, F344 rats received i.v. injections with a natural killer-resistant mammary adenocarcinoma, MADB106, and, for hepatic metastases, animals received an intrasplenic injection of MADB106 tumor cells followed by surgical splenectomy. Three days later, the animals were treated with A-LAK cells alone, A-LAK plus rIL-2. The results indicate that the administration of unfractionated LAK cells plus interleukin 2 (IL-2) was effective in reducing established lung or liver metastases in this rat model. However, the results also indicate that purified populations of A-LAK cells in combination with rIL-2 demonstrate dramatic and superior antimetastatic effect when compared to LAK cells cultured under standard conditions. The antimestatic effects of standard LAK cells or A-LAK cells plus IL-2 translated into significant survival benefits compared to animals receivingno therapy or IL-2 therapy alone. Survival after therapy with A-LAK cells plus IL-2 was significantly prolonged compared to treatment with standard LAK cells. These data suggest that purified populations of LAK cells (derived from natural killer cells) may prove superior for adoptive immunotherapy ion the clinical setting.

This publication has 18 references indexed in Scilit: